Gyroscope Therapeutics recently commenced phase 1/2 clinical trials on a retinal gene therapy for dry age-related macular degeneration.

Gyroscope Therapeutics, a UK-based retinal gene therapy developer partly based on University of Cambridge research, has received an undisclosed sum from Cambridge Innovation Capital, the university’s affiliate patient capital fund. Gyroscope develops retinal gene therapies for dry age-related macular degeneration (AMD) that target genetic factors and inflammations associated with the disease. In dry AMD, small…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.